IVERMECTIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ivermectin, and what generic alternatives are available?
Ivermectin is a drug marketed by Padagis Israel, Teva Pharms Usa, Zydus Lifesciences, Taro, and Edenbridge Pharms. and is included in six NDAs.
The generic ingredient in IVERMECTIN is ivermectin. There are five drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the ivermectin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ivermectin
A generic version of IVERMECTIN was approved as ivermectin by EDENBRIDGE PHARMS on October 24th, 2014.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for IVERMECTIN?
- What are the global sales for IVERMECTIN?
- What is Average Wholesale Price for IVERMECTIN?
Summary for IVERMECTIN
US Patents: | 0 |
Applicants: | 5 |
NDAs: | 6 |
Finished Product Suppliers / Packagers: | 14 |
Raw Ingredient (Bulk) Api Vendors: | 77 |
Clinical Trials: | 205 |
Patent Applications: | 3,087 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for IVERMECTIN |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for IVERMECTIN |
What excipients (inactive ingredients) are in IVERMECTIN? | IVERMECTIN excipients list |
DailyMed Link: | IVERMECTIN at DailyMed |
![IVERMECTIN drug patent expirations Drug patent expirations by year for IVERMECTIN](/p/graph/s/t/IVERMECTIN-patent-expirations.png)
![Drug Prices for IVERMECTIN](/p/graph/drug-price/IVERMECTIN.png)
Recent Clinical Trials for IVERMECTIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Public Health Institute of Liberia | Phase 2 |
Vector Borne & Neglected Tropical Disease Control Division, Ministry of Health, Uganda | Phase 3 |
Insel Gruppe AG, University Hospital Bern | Phase 2 |
Pharmacology for IVERMECTIN
Drug Class | Antiparasitic Pediculicide |
Medical Subject Heading (MeSH) Categories for IVERMECTIN
Anatomical Therapeutic Chemical (ATC) Classes for IVERMECTIN
Paragraph IV (Patent) Challenges for IVERMECTIN
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
SKLICE | Lotion | ivermectin | 0.50% | 202736 | 1 | 2017-09-01 |
SOOLANTRA | Cream | ivermectin | 1% | 206255 | 1 | 2016-12-30 |
US Patents and Regulatory Information for IVERMECTIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Padagis Israel | IVERMECTIN | ivermectin | CREAM;TOPICAL | 210225-001 | Apr 13, 2020 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Taro | IVERMECTIN | ivermectin | LOTION;TOPICAL | 210720-001 | May 6, 2020 | OTC | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Teva Pharms Usa | IVERMECTIN | ivermectin | CREAM;TOPICAL | 210019-001 | Sep 13, 2019 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |